Kardigan is a clinical-stage cardiovascular biotechnology company founded by Tassos Gianakakos, the former CEO of MyoKardia (acquired by Bristol-Myers Squibb for $13B), with a portfolio of in-licensed cardiovascular drug candidates targeting cardiomyopathies and related heart conditions.
Company Info
Funding & Investor Relations
Filed to raise $320M to $369M in a Nasdaq IPO in June 2026, with three in-licensed cardiovascular programs.
Upcoming Milestones & Key Dates
Expected close of Nasdaq IPO at $320-369M
Phase 2 KARDIA-HCM interim data for KDG-101 in HCM
Clinical Development Pipeline
Recent News
Kardigan is pitching a $320M IPO built around three in-licensed heart drugs and a CEO track record from prior cardiovascular launches, betting that an aging pipeline of borrowed cardio assets can be assembled into a focused commercial story.
Kardigan is pursuing a $320M IPO on Nasdaq to fund three cardiovascular drugs in-licensed from larger pharmas, led by a chief executive with a track record in cardio drug development.
Kardigan, the cardiology biotech led by a former MyoKardia executive, has filed to raise up to $369M in a US IPO to fund a pipeline of three in-licensed cardiovascular programs targeting cardiomyopathies and related heart conditions.
Leadership Team
Careers & Job Openings